본문으로 건너뛰기
← 뒤로

Correction: Proteomic-based stratification of intermediate-risk prostate cancer patients.

1/5 보강
Life science alliance 2026 Vol.9(2)
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
환자: Gleason grade groups 2 and 3 and predict the risk of biochemical recurrence
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
This study demonstrates the ability of a protein-based signature to risk-stratify prostate cancer patients with Gleason grade groups 2 and 3 and predict the risk of biochemical recurrence.

Zhong Q, Sun R, Aref AT, Noor Z, Anees A, Zhu Y, Lucas N, Poulos RC, Lyu M, Zhu T, Chen GB, Wang Y, Ding X, Rutishauser D, Rupp NJ, Rueschoff JH, Poyet C, Hermanns T, Fankhauser C, Rodríguez Martínez M, Shao W, Buljan M, Neumann JF, Beyer A, Hains PG, Reddel RR, Robinson PJ, Aebersold R, Guo T, Wild PJ

📝 환자 설명용 한 줄

This study demonstrates the ability of a protein-based signature to risk-stratify prostate cancer patients with Gleason grade groups 2 and 3 and predict the risk of biochemical recurrence.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Zhong Q, Sun R, et al. (2026). Correction: Proteomic-based stratification of intermediate-risk prostate cancer patients.. Life science alliance, 9(2). https://doi.org/10.26508/lsa.202503547
MLA Zhong Q, et al.. "Correction: Proteomic-based stratification of intermediate-risk prostate cancer patients.." Life science alliance, vol. 9, no. 2, 2026.
PMID 41326175

Abstract

This study demonstrates the ability of a protein-based signature to risk-stratify prostate cancer patients with Gleason grade groups 2 and 3 and predict the risk of biochemical recurrence.

같은 제1저자의 인용 많은 논문 (5)